| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 2652 | 2015 |
| Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition … S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ... Journal of clinical oncology 31 (7), 860-867, 2013 | 1749 | 2013 |
| Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ... Annals of oncology 25 (8), 1544-1550, 2014 | 1358 | 2014 |
| CD4+ follicular helper T cell infiltration predicts breast cancer survival C Gu-Trantien, S Loi, S Garaud, C Equeter, M Libin, A De Wind, M Ravoet, ... The Journal of clinical investigation 123 (7), 2873-2892, 2013 | 1014 | 2013 |
| Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis S Turajlic, K Litchfield, H Xu, R Rosenthal, N McGranahan, JL Reading, ... The lancet oncology 18 (8), 1009-1021, 2017 | 846 | 2017 |
| Clinical relevance of host immunity in breast cancer: from TILs to the clinic P Savas, R Salgado, C Denkert, C Sotiriou, PK Darcy, MJ Smyth, S Loi Nature reviews Clinical oncology 13 (4), 228-241, 2016 | 825 | 2016 |
| Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis P Savas, B Virassamy, C Ye, A Salim, CP Mintoff, F Caramia, R Salgado, ... Nature medicine 24 (7), 986-993, 2018 | 815 | 2018 |
| Neoantigen-directed immune escape in lung cancer evolution R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ... Nature 567 (7749), 479-485, 2019 | 723 | 2019 |
| Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial L Voorwerk, M Slagter, HM Horlings, K Sikorska, KK van de Vijver, ... Nature medicine 25 (6), 920-928, 2019 | 704 | 2019 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 675 | 2017 |
| Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers S Loi, D Drubay, S Adams, G Pruneri, PA Francis, M Lacroix-Triki, ... Journal of clinical oncology 37 (7), 559, 2019 | 665 | 2019 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 604 | 2017 |
| Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib … R Salgado, C Denkert, C Campbell, P Savas, P Nuciforo, C Aura, ... JAMA oncology 1 (4), 448-455, 2015 | 597 | 2015 |
| Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer R Salgado, S Junius, I Benoy, P Van Dam, P Vermeulen, E Van Marck, ... International journal of cancer 103 (5), 642-646, 2003 | 585 | 2003 |
| The 2019 WHO classification of tumours of the breast PH Tan, I Ellis, K Allison, E Brogi, SB Fox, S Lakhani, AJ Lazar, EA Morris, ... Histopathology 77 (2), 2020 | 542 | 2020 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 530 | 2016 |
| Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 506 | 2016 |
| Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group TO Nielsen, SCY Leung, DL Rimm, A Dodson, B Acs, S Badve, C Denkert, ... JNCI: Journal of the National Cancer Institute 113 (7), 808-819, 2021 | 443 | 2021 |
| Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in … MV Dieci, N Radosevic-Robin, S Fineberg, G Van den Eynden, N Ternes, ... Seminars in cancer biology 52, 16-25, 2018 | 415* | 2018 |
| Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival IH Benoy, R Salgado, P Van Dam, K Geboers, E Van Marck, S Scharpé, ... Clinical Cancer Research 10 (21), 7157-7162, 2004 | 403 | 2004 |
